About ardelyx inc - ARDX
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
ARDX At a Glance
Ardelyx, Inc.
400 Fifth Avenue
Waltham, Massachusetts 02451
| Phone | 1-510-745-1700 | Revenue | 407.32M | |
| Industry | Pharmaceuticals: Major | Net Income | -61,599,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 22.093% | |
| Fiscal Year-end | 12 / 2026 | Employees | 489 | |
| View SEC Filings |
ARDX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.45 |
| Price to Book Ratio | 8.533 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -35.563 |
| Enterprise Value to Sales | 3.311 |
| Total Debt to Enterprise Value | 0.154 |
ARDX Efficiency
| Revenue/Employee | 832,965.235 |
| Income Per Employee | -125,969.325 |
| Receivables Turnover | 5.669 |
| Total Asset Turnover | 0.868 |
ARDX Liquidity
| Current Ratio | 4.315 |
| Quick Ratio | 4.115 |
| Cash Ratio | 2.987 |
ARDX Profitability
| Gross Margin | 89.542 |
| Operating Margin | -10.06 |
| Pretax Margin | -14.885 |
| Net Margin | -15.123 |
| Return on Assets | -13.126 |
| Return on Equity | -36.209 |
| Return on Total Capital | -16.431 |
| Return on Invested Capital | -17.635 |
ARDX Capital Structure
| Total Debt to Total Equity | 124.561 |
| Total Debt to Total Capital | 55.469 |
| Total Debt to Total Assets | 41.359 |
| Long-Term Debt to Equity | 123.675 |
| Long-Term Debt to Total Capital | 55.074 |